ReviewClinical journal of the American Society of Nephrology : CJASN2026
Optimizing Dialysis Vascular Access: Moving beyond Fistula First.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mortality risk associated with permanent central venous catheter use in the oldest-old population: a nationwide cohort study.The Korean journal of internal medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
For many years, the vascular access guidelines recommended placement of arteriovenous fistulas (AVFs) in preference to arteriovenous grafts (AVGs) because AVFs had superior long-term patency, required fewer interventions to maintain patency, and were associated with lower costs of vascular access management. However, subsequent research has questioned the Fistula First strategy (placing an AVF whenever the vascular anatomy is suitable). First, AVF nonmaturation is substantial (30%-40%) and even higher among women, older patients, and those with peripheral vascular disease. Second, about half of AVFs require surgical or percutaneous interventions to assist maturation. Moreover, AVFs that require assisted maturation have shorter patency and require more frequent interventions, as compared with AVFs with unassisted maturation. Third, in an intent-to-treat analysis, when the Fistula First strategy is followed in patients initiating hemodialysis with a central venous catheter, the annual frequency of access procedures and the overall cost of access management are substantially greater for AVFs than AVGs. Fourth, in patients with advanced CKD undergoing predialysis access AVF rather than AVG placement, initiation of dialysis with a central venous catheter is much more common. An alternative strategy is a more selective one, in which patients at high risk of AVF nonmaturation preferentially receive an AVG, even if the vascular anatomy is suitable for an AVF. As compared with the Fistula First strategy, the more selective vascular access strategy is associated with fewer access procedures and a lower annual cost of access management. In summary, a more nuanced, patient-centered approach to vascular access may improve access outcomes, decrease the burden of access procedures, and lower the overall costs of vascular access management. This realization has been distilled in the 2019 updated Kidney Disease Outcomes Quality Initiative Vascular Access Guidelines, which exhort nephrologists and surgeons to place the right access in the right patient at the right time for the right reason.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.